CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.
Saved in:
| Title: | CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy. |
|---|---|
| Authors: | Qin X; School of Medicine, Nankai University, Tianjin, China.; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China., Chang Y; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China., Qiu Y; School of Life Sciences, Biomedical Pioneering Innovation Center, Peking University, Beijing, China., Han W; School of Medicine, Nankai University, Tianjin, China. hanwdrsw@163.com.; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. hanwdrsw@163.com., Nie J; Department of Bio-therapeutic, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. nnjj2002@163.com. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2026 Jan 24; Vol. 12 (1). Date of Electronic Publication: 2026 Jan 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-026-00895-3 |
